Boehringer Ingelheim and CDR-Life have reported positive outcomes from the Phase I clinical trial of BI 771716, a new ...

The one-time intravitreally delivered gene therapy is for the treatment of retinitis pigmentosa (RP). The US Food and Drug Administration has granted an Orphan Drug Designation (ODD) for SKG1108 from ...

Durga Borkar, MD, sat down with Sydney Crago of Modern Retina to discuss one of her presentations on the first time phase 2 ...

EyeBio’s main asset is Restoret, an intravitreally delivered trispecific antibody that acts as an agonist of the Wnt signalling pathway and is in the phase 1b/2a AMARONE study in DME and ...

Amgen’s Pavblu (aflibercept-ayyh) is the fifth biosimilar referencing Eylea (aflibercept) to be approved for American ...

Skyline Therapeutics (Shanghai) Co. Ltd.’s SKG-1108, a novel one-time intravitreally delivered gene therapy, has been awarded U.S. orphan drug designation for the treatment of retinitis pigmentosa.

The one-time intravitreally delivered candidate is being evaluated in a Phase I/II clinical trial (NCT05986864) in patients with nAMD. The nAMD market is expected to reach $27.5bn across the seven ...

*Syndromes include WNF, West Nile meningitis, West Nile encephalitis and WNP. ‡ Overall, WNND represents 1% of human WNV infections. § WNP may occur in the context of any other manifestation of ...

The trial assessed the tolerability, safety, and pharmacokinetics of varying doses of BI 771716 administered intravitreally to patients aged 50 years and above. It aimed to evaluate the tolerance ...